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Methylation of TET2, CBL and CEBPA in Ph-negative
myeloproliferative neoplasms
C S Chim,1 T S Wan,2 T K Fung,1 K F Wong3
ABSTRACT
A loss-of-function mutation of TET2, CBL and CEBPA has
been implicated in the pathogenesis or leukaemic
transformation of myeloproliferative neoplasm. As
tumour suppressor genes may potentially be inactivated
by promoter hypermethylation, the authors studied the
methylation status of these genes in three cell lines and
diagnostic marrow samples from 45 patients with
myeloproliferative neoplasm (MPN) (essential
thrombocythaemia, N¼34; polycythaemia vera, N¼7
and primary myelofibrosis, N¼4) by methylation-specific
PCR. TET2 was heterozygously methylated in MEG-01
and K562 but completely unmethylated in HEL. On the
other hand, both CBL and CEBPA were completely
unmethylated in all three cell lines. In the primary
marrow samples, methylation of TET2 occurred in two
(5.9%) patients with essential thrombocythaemia (4.4%
of all patients), both without JAK2 V617 mutation, but
not in polycythaemia vera or primary myelofibrosis. There
was no association between TET2 methylation with the
type of MPN (p¼0.713). Hypermethylation of CBL or
CEBPA was not detected in any patients. In summary,
methylation of TET2, CBL and CEBPA is infrequent in
MPN at diagnosis. The role of methylation of these genes
at the time of leukaemic transformation warrants further
study.
INTRODUCTION
Philadelphia-negative (Pheve) myeloproliferative
neoplasm (MPN) is a stem cell disease with prolif-
eration of myeloid compartment, leading to devel-
opment of distinct clinical entities including
polycythaemia vera (PV), essential thrombocy-
thaemia (ET) and primary myelofibrosis (PMF).1e3
JAK2 V617F mutation, resulting in constitutive
activation of JAK-STAT signalling, occurs in about
half of the patients with ET and PMF but in more
than 90% of patients with PV.1 The recent
discovery of JAK2 V617F in Pheve MPN is a major
advance in the understanding of the pathogenesis
of MPN, which is characterised by proliferation of
the myeloid compartment resulting in distinct
clinical entities.
Gene methylation is an alternative mechanism of
gene inactivation, and various tumour suppressor
genes regulating the cell cycle, apoptosis and cell
signalling have been shown to be hypermethylated
in haematological malignancies.4
Recently, inactivating mutations of several
tumour suppressor genes have been detected in
various myeloproliferative diseases or myeloid
malignancies, including Casitas B lineage lymphoma
(CBL), TET2 and CEBPA. CBL, which is localised
to 11q23, possesses an E3 ubiquitinated ligase
responsible for termination of activated tyrosine
kinases. The tumour suppressor role of CBL has been
demonstrated in mouse models, in which c-Cble/e
mice displayed splenomegaly and an expanded
haematopoietic progenitor pool, and accelerated
blastic crisis when introduced into a BCR-ABL
transgenic background.5 On the other hand, TET2
(TEToncogene family, member 2), localised to 4q24,
is a putative tumour suppressor gene shown to be
deleted in MDS/AML and was also shown to be
mutated in 24 (12%) of 198 patients with MPN
(with or without the JAK2 V617F mutation).6
Finally, CCAAT/enhancer binding protein (C/EBP),
a, (CEBPA) which is localised to 19q13, is an
important tumour suppressor gene regulating
myeloid differentiation. Mutation, translocation
and methylation of CEBPA have been demonstrated
in AML.7 8 Moreover, knock-in mice with a targeted
mutation in the CEBPA basic region, which
specifically inhibits the CEBPA-E2F interaction,
predisposed mice to a myeloproliferative disorder.9
As these three genes are putative tumour
suppressors important in the pathogenesis of
myeloid malignancies, we hypothesised that these
genes might be inactivated by gene hypermethylation
in patients with MPN.
MATERIALS AND METHODS
Cell lines
MEG-01 and K562 cells were kindly provided by Dr
Yang Mo, Department of Paediatrics, Queen Mary
Table 1 Clinical demographics
No of patients (%)
Myeloproliferative neoplasm type 45 (100%)
Polycythaemia vera 7 (15.6%)
Essential thrombocythaemia 34 (75.5%)
Primary myelofibrosis 4 (8.9%)
Gender
Male 24 (53.3%)
Female 21 (46.7%)
Age (years)
Median (range) 67.5 (28e89)
CBP
Hb (g/dl) 13.3 (9e22)
Leucocyte count (3109/l) 14.4 (7e28)
Platelet count (3109/l) 848 (196e2275)
Symptoms at diagnosis*
Asymptomatic 25 (62.5%)
Bleeding 4 (10%)
Erythromelalgia 4 (10%)
Stroke 2 (5%)
Abdominal pain 3 (7.5%)
Blurred vision 1 (2.5%)
Weight loss 1 (2.5%)
*Data available in 40 patients.
CBP, complete blood picture.
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Figure 1 (A) CpG island of TET2 gene with location and sequence of methylation-specific polymerase chain reaction (MSP) primers (mf, forward M-
MSP primer; mr, reverse M-MSP primer; uf, forward U-MSP primer; ur, reverse U-MSP primer). (B) Direct sequencing of methylated positive control
showing complete bisulfite conversion, and authenticity of MSP amplification. (C) M- and U-MSP of normal unmethylated controls (N1eN8), cell lines
(C1eC3) and primary marrow samples (S1eS8). M, molecular weight marker; NC, normal unmethylated control; PC, methylated positive control.
J Clin Pathol 2010;63:942e946. doi:10.1136/jcp.2010.080218 943
Short report
 group.bmj.com on July 6, 2011 - Published by jcp.bmj.comDownloaded from 
Hospital, Hong Kong; and HEL from Dr Dong-Er Zhang,
Department of Pathology and Molecular Biology, Moores Cancer
Centre, University of California, San Diego, USA.
Patient and diagnosis
Diagnosis of MPN including ET, PV and PMF was based on
WHO criteria.1 The clinical demographics of the patients are
illustrated in table 1.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from cell lines and primary bone marrow
samples at diagnosis using a standard method. Using computer
software, the presence of CpG islands at the corresponding gene
promoters were determined, and unmethylated and methylated
MSP primers were designed. Treatment of DNA with bisulfite
for conversion of unmethylated cytosine to uracil (but unaf-
fecting methylated cytosine) was performed with a commer-
cially available kit (CpGenome DNA modification kit,
Chemicon, New York). Methylation-specific PCR (MSP) was
then validated in methylated (positive) and unmethylated
(negative or normal) controls (DNA from normal cells) with
methylated and unmethylated MSP primers.
RESULTS
Presence of a CpG island at the 59 untranslated regions
(UTRs) for the all three genes was confirmed (figures 1e3).
Figure 2 (A) CpG island of CBL gene with location and sequence of methylation-specific polymerase chain reaction (MSP) primers (mf, forward M-
MSP primer; mr, reverse M-MSP primer; uf, forward U-MSP primer; ur, reverse U-MSP primer). (B) Direct sequencing of methylated positive control
showing complete bisulfite conversion, and authenticity of MSP amplification. (C) M- and U-MSP of normal unmethylated controls (N1eN8), cell lines
(C1eC3) and primary marrow samples (S1eS8). M, molecular weight marker; NC, normal unmethylated control; PC, methylated positive control.
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Methylation-specific PCR (MSP) was then performed in meth-
ylated (positive) and unmethylated (negative or normal)
controls (DNA from normal cells) with methylated and unme-
thylated MSP primers, which showed methylation of genes in
the positive but not the normal DNA controls (figures 1e3).
Direct sequencing of the methylated MSP of positive control
confirmed specificity of the methylated amplification, in which
methylated cytosine remained as cytosine upon sequencing
(underlined) while unmethylated cytosine appeared as thymi-
dine (figures 1e3). MSP was performed on cells from these three
cell lines, HEL, MEG-01 and K562. HEL carried JAK2 V617F
mutation, and MEG-01 and K562 were derived from blastic
transformation of patients with chronic myeloid leukaemia.
TET2 was heterozygously methylated in MEG-01 and K562
Figure 3 (A) CpG island of CEBPA gene with location and sequence of methylation-specific polymerase chain reaction (MSP) primers (mf, forward
M-MSP primer; mr, reverse M-MSP primer; uf, forward U-MSP primer; ur, reverse U-MSP primer). (B) Direct sequencing of methylated positive control
showing complete bisulfite conversion, and authenticity of MSP amplification. (C) M- and U-MSP of normal unmethylated controls (N1eN8), cell lines
(C1eC3) and primary marrow samples (S1eS8). M, molecular weight marker; NC, normal unmethylated control; PC, methylated positive control.
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but completely unmethylated in HEL (figure 1). On the other
hand, both CBL and CEBPA were completely unmethylated in
all three cell lines (figures 2, 3).
In the primary diagnostic marrow samples, methylation of
TET2 occurred in two (5.9%) patients with ET (4.4% of all
patients) (figure 1), and none of the patients carried hyper-
methylation of CBL or CEBPA (figures 2, 3). These two patients
did not carry a JAK2 V617F mutation. However, there was no
association between TET2 methylation with the type of MPN
(p¼0.713).
DISCUSSION
Recent studies strongly suggested that TET2 is a tumour
suppressor gene as a TET2 mutation has been demonstrated to
be acquired in 12e24% of myeloid neoplasms including AML,
MDS, CMML and MPN. Moreover, while occasional patients
possessed homozygous TET2 deletion, the majority showed
a TET2 mutation together with gene deletion, thereby impli-
cating a tumour suppressor role of TET2 in myeloid neoplasms.
In particular, it is mutated in 12e13% of MPN including ET, PV
and PMF.6 10 Therefore, we postulated that TET2 hyper-
methylation might occur. Indeed, it was demonstrated in two
(5.9%) patients in this cohort, and hence might be a possible
mechanism to result in biallelic gene inactivation, and hence
fulfil Knudson’s hypothesis, which proposed that both alleles of
a tumour suppressor gene have to be inactivated, usually by
deletion and/or mutation, for complete abrogation of its func-
tion.11 The low frequency of TET2 gene hypermethylation was
similar to the finding of absence of TET2 hypermethylation in
another cohort of 354 MPN patients.12 CBL is a tumour
suppressor gene responsible for termination of receptor-
associated tyrosine kinase signalling. The most common
abnormality in myeloid neoplasms, in particular CMML, is
the acquisition of uniparental disomy of a mutant allele of
CBL, leading to prolonged activation of tyrosine kinases after
cytokine stimulation.5 In a study of CBL mutation in 577
patients with various haematological myeloproliferative disor-
ders including 151 patients with Pheve MPN (74 PV, 53 PMF
and 24 ET), the CBL mutation was detected in 26 patients.
Three patients with PMF but none of those with PV or ET
(ie, 2% of the Pheve MPN patients) were found to carry CBL
mutation.13 Our study showed that there was no methylation
of CBL in MPN. Therefore, CBL mutation or methylation
appeared infrequent in Pheve MPNs.
Finally, CEBPA methylation has been shown in up to 51% of
AML patients,14 and hence might be important in myeloid
malignancy. It is one of the first reports of the absence of
methylation of this gene in MPN patients. However, as
inactivation of CEBPA might be responsible for leukaemic
transformation, it will be important to study CEBPA hyper-
methylation in patients with leukaemia transforming from
underlying MPN.
In summary, methylation of TET2, CBL and CEBPA is infre-
quent in MPN at diagnosis. The role of methylation of these
genes at the time of leukaemic transformation warrants further
study.
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Take-home messages
< Loss-of-function mutation of TET2, CBL and CEBPA has been
implicated in the pathogenesis or leukaemic transformation of
MPN.
< Methylation of TET2, CBL and CEBPA is infrequent in MPN at
diagnosis.
< The role of methylation of these genes at the time of
leukaemic transformation warrants further study.
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